Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

Clinicians and policymakers should critically evaluate differences in trial design, end points, and regulatory decisions when interpreting approvals of immune checkpoint inhibitors and targeted ...

Ellipses Pharma ("Ellipses"), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for ...

The sNDA for sevabertinib is supported by data from the SOHO-01 trial, showing a median duration of response of 11.0 months and a 71% objective response rate in patients with HER2-mutated NSCLC who ...

WAUSAU, Wis. (WSAW) - In the past, being diagnosed with small-cell lung cancer seemed to be a death sentence. This type of cancer is known as one of the most aggressive and deadliest forms of cancer.

The two main categories for lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Large cell lung cancer (LCLC) is a type of NSCLC. While the conditions share some ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

SCLC diagnosis involves imaging, biopsies, and lab tests to assess tumor spread and guide treatment decisions. Treatment options vary by stage, with surgery, chemotherapy, radiation, and immunotherapy ...